These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 16848688)

  • 1. Targeting protein aggregation in neurodegeneration--lessons from polyglutamine disorders.
    Weydt P; La Spada AR
    Expert Opin Ther Targets; 2006 Aug; 10(4):505-13. PubMed ID: 16848688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conformational changes and aggregation of expanded polyglutamine proteins as therapeutic targets of the polyglutamine diseases: exposed beta-sheet hypothesis.
    Nagai Y; Popiel HA
    Curr Pharm Des; 2008; 14(30):3267-79. PubMed ID: 19075705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intracellular degradation of misfolded proteins in polyglutamine neurodegenerative diseases.
    Li X; Li H; Li XJ
    Brain Res Rev; 2008 Nov; 59(1):245-52. PubMed ID: 18773920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strategies for the inhibition of protein aggregation in human diseases.
    Bartolini M; Andrisano V
    Chembiochem; 2010 May; 11(8):1018-35. PubMed ID: 20401887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heat shock proteins as potential targets for protective strategies in neurodegeneration.
    Kampinga HH; Bergink S
    Lancet Neurol; 2016 Jun; 15(7):748-759. PubMed ID: 27106072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A rapid cellular FRET assay of polyglutamine aggregation identifies a novel inhibitor.
    Pollitt SK; Pallos J; Shao J; Desai UA; Ma AA; Thompson LM; Marsh JL; Diamond MI
    Neuron; 2003 Nov; 40(4):685-94. PubMed ID: 14622574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biologically active molecules that reduce polyglutamine aggregation and toxicity.
    Desai UA; Pallos J; Ma AA; Stockwell BR; Thompson LM; Marsh JL; Diamond MI
    Hum Mol Genet; 2006 Jul; 15(13):2114-24. PubMed ID: 16720620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential therapeutic targets in polyglutamine-mediated diseases.
    Katsuno M; Watanabe H; Yamamoto M; Sobue G
    Expert Rev Neurother; 2014 Oct; 14(10):1215-28. PubMed ID: 25190502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heat shock proteins: therapeutic drug targets for chronic neurodegeneration?
    Sajjad MU; Samson B; Wyttenbach A
    Curr Pharm Biotechnol; 2010 Feb; 11(2):198-215. PubMed ID: 20166961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ROCK inhibition in models of neurodegeneration and its potential for clinical translation.
    Koch JC; Tatenhorst L; Roser AE; Saal KA; Tönges L; Lingor P
    Pharmacol Ther; 2018 Sep; 189():1-21. PubMed ID: 29621594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone deacetylase inhibitors: possible implications for neurodegenerative disorders.
    Hahnen E; Hauke J; Tränkle C; Eyüpoglu IY; Wirth B; Blümcke I
    Expert Opin Investig Drugs; 2008 Feb; 17(2):169-84. PubMed ID: 18230051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polyglutamine and neurodegeneration: structural aspects.
    Masino L
    Protein Pept Lett; 2004 Jun; 11(3):239-48. PubMed ID: 15182225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein aggregation and ER stress.
    Ogen-Shtern N; Ben David T; Lederkremer GZ
    Brain Res; 2016 Oct; 1648(Pt B):658-666. PubMed ID: 27037184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New insights of poly(ADP-ribosylation) in neurodegenerative diseases: A focus on protein phase separation and pathologic aggregation.
    Liu C; Fang Y
    Biochem Pharmacol; 2019 Sep; 167():58-63. PubMed ID: 31034795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular chaperones biochemistry and role in neurodegenerative diseases.
    Chaari A
    Int J Biol Macromol; 2019 Jun; 131():396-411. PubMed ID: 30853582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prion-Like Characteristics of Polyglutamine-Containing Proteins.
    Pearce MMP; Kopito RR
    Cold Spring Harb Perspect Med; 2018 Feb; 8(2):. PubMed ID: 28096245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protein misfolding in the late-onset neurodegenerative diseases: common themes and the unique case of amyotrophic lateral sclerosis.
    Mulligan VK; Chakrabartty A
    Proteins; 2013 Aug; 81(8):1285-303. PubMed ID: 23508986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurotoxicity Pathways in Drosophila Models of the Polyglutamine Disorders.
    Krench M; Littleton JT
    Curr Top Dev Biol; 2017; 121():201-223. PubMed ID: 28057300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of Molecular Chaperones in Huntington's Disease and Other Polyglutamine Disorders.
    Reis SD; Pinho BR; Oliveira JMA
    Mol Neurobiol; 2017 Oct; 54(8):5829-5854. PubMed ID: 27660272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Molecular therapy targeting protein misfolding and aggregation for the polyglutamine diseases].
    Nagai Y
    Rinsho Shinkeigaku; 2009 Nov; 49(11):913-6. PubMed ID: 20030247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.